Regenerative Therapies

Bringing MSC into clinical care to prevent inflammation-based diseases. Mesenchymal stromal cells have been shown to exhibit a great therapeutical potential in various diseases. However, up until now clinical application was limited by the lack of availability of clinical grade MSC in large quantities. A method has been developed by our group to isolate fetal MSC at clinical grade. The method was patented (DE102016114043B3) and is currently in migration into a university-based spin-off company. Within the MASC-collaboration these MSC are currently tested in clinical trials (OHRI, CHEO, SCRM). Currently, this cells are also used as a therapeutic agent to treat Covid-19 associated ARDS. Furthermore, a trial is planned to test efficacy in patients with steroid refractory GvHD. The project receives funding from different sources, including the BMBF within the SaxoCell Cluster4Future.

Group

Gruppenfoto_regenertive therapies

Tino Hammer, Marius Möbius, Nadine Münch, Mario Rüdiger, Daniel Freund

Collaborations

The working group is part of the newly established SaxoCell Cluster4Future, which aims to bring celular therapy into clinical care.

Sinclair Center for Regenerative Medicine (SCRM), Ottawa Hospital Research Institute (OHRI) and the Cildren`s Hospital of Eastern Ontario (CHEO); Ottawa, Canada;

University of Texas Health Sciences Center at San Antonio (UTHSCSA), USA;

King`s College, London (KCL), UK;

Medizinische Hochschule Hannover (MHH);

Center for Pediatric Clinical Studies, Universität Tübingen (CPCS);

Publications

Prophylactic Administration of Mesenchymal Stromal Cells Does Not Prevent Arrested Lung Development in Extremely Premature-Born Non-Human Primates. Möbius MA, Seidner SR, McCurnin DC, Menschner L, Fürböter-Behnert I, Schönfeld J, Marzahn J, Freund D, Münch N, Hering S, Mustafa SB, Anzueto DG, Winter LA, Blanco CL, Hanes MA, Rüdiger M, Thébaud B. Stem Cells Transl Med. 2023 Feb 1:szac088. doi: 10.1093/stcltm/szac088. Online ahead of print

Pulmonary and Neurologic Effects of Mesenchymal Stromal Cell Extracellular Vesicles in a Multifactorial Lung Injury Model. Lithopoulos MA, Strueby L, O'Reilly M, Zhong S, Möbius MA, Eaton F, Fung M, Hurskainen M, Cyr-Depauw C, Suen C, Xu L, Collins JJP, Vadivel A, Stewart DJ, Burger D, Thébaud B.Am J Respir Crit Care Med. 2022 Mar 14. doi: 10.1164/rccm.202012-4520OC. Online ahead of print.

Perinatal Hyperoxia and Developmental Consequences on the Lung-Brain Axis.Obst S, Herz J, Alejandre Alcazar MA, Endesfelder S, Möbius MA, Rüdiger M, Felderhoff-Müser U, Bendix I.Oxid Med Cell Longev. 2022 Feb 24;2022:5784146. doi: 10.1155/2022/5784146. eCollection 2022.

Systematic analysis of candidate reference genes for gene expression analysis in hyperoxia-based mouse models of bronchopulmonary dysplasia. Linge M, Möbius MA, Rösen-Wolff A, Winkler S.Am J Physiol Lung Cell Mol Physiol. 2021 Oct 1;321(4):L718-L725. doi: 10.1152/ajplung.00143.2021. Epub 2021 Aug 11.

Late Rescue Therapy with Cord-Derived Mesenchymal Stromal Cells for Established Lung Injury in Experimental Bronchopulmonary Dysplasia. O'Reilly M, Möbius MA, Vadivel A, Ionescu L, Fung M, Eaton F, Greer JJ, Thébaud B. Stem Cells Dev. 2020 Mar 15;29(6):364-371. doi: 10.1089/scd.2019.0116

How to introduce MSC-based therapy for the developing lung safely into clinical care? Rüdiger M, Kirpalani H, Steinhorn R, Davis JM, Thebaud B. Pediatr Res. 2020 Sep;88(3):365-368. doi: 10.1038/s41390-020-0758-0

Oxygen Disrupts Human Fetal Lung Mesenchymal Cells. Implications for Bronchopulmonary Dysplasia. Möbius MA, Freund D, Vadivel A, Koss S, McConaghy S, Ohls RK, Rüdiger M, Thébaud B. Am J Respir Cell Mol Biol. 2019 May;60(5):592-600. doi: 10.1165/rcmb.2018-0358OC

Impaired Angiogenic Supportive Capacity and Altered Gene Expression Profile of Resident CD146+ Mesenchymal Stromal Cells Isolated from Hyperoxia-Injured Neonatal Rat Lungs. Collins JJP, Lithopoulos MA, Dos Santos CC, Issa N, Möbius MA, Ito C, Zhong S, Vadivel A, Thébaud B. Stem Cells Dev. 2018 Aug 15;27(16):1109-1124. doi: 10.1089/scd.2017.0145

Bronchopulmonary Dysplasia: Where Have All the Stem Cells Gone?: Origin and (Potential) Function of Resident Lung Stem Cells. Möbius MA, Thébaud B. Chest. 2017 Nov;152(5):1043-1052. doi: 10.1016/j.chest.2017.04.173

Human Umbilical Cord Mesenchymal Stromal Cells Improve Survival and Bacterial Clearance in Neonatal Sepsis in Rats. Zhu Y, Xu L, Collins JJP, Vadivel A, Cyr-Depauw C, Zhong S, Mense L, Möbius MA, Thébaud B. Stem Cells Dev. 2017 Jul 15;26(14):1054-1064. doi: 10.1089/scd.2016.0329

Cell Therapy for Bronchopulmonary Dysplasia: Promises and Perils. Möbius MA, Thébaud B. Paediatr Respir Rev. 2016 Sep;20:33-41. doi: 10.1016/j.prrv.2016.06.001

Isolation of CD146+ Resident Lung Mesenchymal Stromal Cells form Rat Lungs. Collins JJ, Möbius MA, Thébaud B. J Vis Exp. 2016 Jun 17;(112):53782. doi: 10.3791/53782

Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia. Möbius MA, Rüdiger M. Mol Cell Pediatr. 2016 Dec;3(1):18. doi: 10.1186/s40348-016-0046-6